Rise of lasR mutant Pseudomonas aeruginosa keratitis

lasR突变型铜绿假单胞菌角膜炎的兴起

基本信息

  • 批准号:
    10437757
  • 负责人:
  • 金额:
    $ 38.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract The NIH funded Steroids for Corneal Ulcers Study found that keratitis caused by naturally occurring lasR mutants of the bacteria Pseudomonas aeruginosa resulted in significantly worse vision outcomes than keratitis caused by wild-type P. aeruginosa. All the isolates, from India, were obtainted between 2006-2010. Using the vast repository at the University of Pittsburgh Campbell Laboratory, which has isolates back to 1992, a concerning trend was observed that lasR mutants have dramatically increased among P. aeruginosa keratitis isolates in the United States. This is a potential public health problem that this study would help to communicate to ophthalmologists and optometrists. The long-term goal of this research is to develop approaches to prevent vision loss caused by infections. The overall objective of this application is to determine the mechanism by which lasR mutants of P. aeruginosa cause worse clinical outcomes. Our central hypothesis is that the LasR transcription factor inhibits expression of genes that influence P. aeruginosa survival on the harsh ocular surface, such that genes upregulated in the mutant confer an increased infectivity phenotype. The rationale for this study is that identifying the mechanisms by which LasR controls ocular virulence will provide a scientific basis to develop therapeutic strategies to combat vision loss. Three specific aims have been designed to interrogate our central hypothesis: 1) to characterize the genetic basis of lasR mutations among the clinical isolate collection at the Campbell Laboratory, and evaluate the extent to which the mutations confer dominant or recessive virulence phenotypes; 2) to test the importance of specific P. aeruginosa genes that have increased expression in lasR mutants for a role in ocular surface survival, establishing corneal infection in a rabbit contact lens infection model, and in inducing corneal inflammation, and 3) to test whether lasR mutants have elevated resistance to ocular surface innate defenses and ophthalmically relevant antibiotic therapy. This study will use a combination of advanced molecular genetics to manipulate bacterial genomes including clinical isolates, next generation sequencing, and well-established in vitro and in vivo models. This study is innovative because current diagnostic approaches do not differentiate between P. aeruginosa strains that cause keratitis, other than antibiotic susceptibility, and this study will introduce a new approach to identify highly vision threatening P. aeruginosa isolates. This study will also evaluate several candidate virulence factors that have not been tested with respect to the eye. The significance of this study is based on two items: A) its high potential to elucidate new pathogenic mechanisms that bacteria wield to establish blinding ocular infections, and the resulting knowledge can ultimately be used to develop approaches to prevent vision loss due to ocular infections, and B) introducing a feasible form of personalized medicine that can be used to alert health care workers to patients most at risk for vision loss.
项目总结/摘要 美国国立卫生研究院资助的类固醇治疗角膜溃疡研究发现, 铜绿假单胞菌的突变体导致的视力结果比角膜炎明显更差 是由野生型铜绿假单胞菌引起的所有来自印度的分离株都是在2006-2010年间获得的。使用 匹兹堡大学坎贝尔实验室的一个巨大的储存库中, 在铜绿假单胞菌角膜炎中观察到lasR突变体显著增加的趋势 隔离在美国。这是一个潜在的公共卫生问题,这项研究将有助于 与眼科医生和验光师沟通。这项研究的长期目标是开发 预防感染引起的视力丧失。本申请的总体目标是确定 铜绿假单胞菌的lasR突变体导致更差临床结果的机制。我们的核心假设 LasR转录因子抑制了影响铜绿假单胞菌存活的基因的表达, 粗糙的眼表面,使得在突变体中上调的基因赋予增加的感染性表型。的 这项研究的基本原理是,确定LasR控制眼部毒力的机制将提供一种新的方法, 科学基础,制定治疗策略,以打击视力下降。三个具体目标是 设计来询问我们的中心假设:1)表征lasR突变的遗传基础, 在坎贝尔实验室收集临床分离株,并评估突变赋予 显性或隐性毒力表型; 2)测试特异性铜绿假单胞菌基因的重要性, 在lasR突变体中表达增加,在眼表存活中起作用, 兔隐形透镜感染模型,并诱导角膜炎症,以及3)测试lasR突变体是否 对眼表先天防御和眼科相关抗生素治疗具有提高的抗性。这 一项研究将使用先进的分子遗传学组合来操纵细菌基因组,包括临床 分离株,下一代测序,以及完善的体外和体内模型。本研究具有创新性 因为目前的诊断方法不能区分引起角膜炎的铜绿假单胞菌菌株, 除了抗生素敏感性之外,这项研究将引入一种新的方法来识别高度视力。 威胁铜绿假单胞菌分离株。这项研究还将评估几个候选毒力因子, 未对眼睛进行测试。本研究的意义基于两个方面:A)其高 阐明细菌产生致盲性眼部感染的新致病机制的潜力, 并且所得到的知识最终可以用于开发预防由于眼内炎引起的视力丧失的方法。 感染,以及B)引入一种可行的个性化药物形式,可用于警告医疗保健 工人对患者最有可能丧失视力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT M SHANKS其他文献

ROBERT M SHANKS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT M SHANKS', 18)}}的其他基金

Rise of lasR mutant Pseudomonas aeruginosa keratitis
lasR突变型铜绿假单胞菌角膜炎的兴起
  • 批准号:
    10181256
  • 财政年份:
    2021
  • 资助金额:
    $ 38.62万
  • 项目类别:
Rise of lasR mutant Pseudomonas aeruginosa keratitis
lasR突变型铜绿假单胞菌角膜炎的兴起
  • 批准号:
    10652442
  • 财政年份:
    2021
  • 资助金额:
    $ 38.62万
  • 项目类别:
NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization
NOT-NS-20-030:使用锚定生物制剂治疗发泡剂诱导的新血管形成
  • 批准号:
    10228255
  • 财政年份:
    2017
  • 资助金额:
    $ 38.62万
  • 项目类别:
Bacterial Factors that Regulate Ocular Host-Pathogen Interactions and Microbial Keratitis
调节眼部宿主-病原体相互作用和微生物角膜炎的细菌因素
  • 批准号:
    9910406
  • 财政年份:
    2017
  • 资助金额:
    $ 38.62万
  • 项目类别:
Novel virulence and exoenzyme regulators
新型毒力和外酶调节剂
  • 批准号:
    8260347
  • 财政年份:
    2010
  • 资助金额:
    $ 38.62万
  • 项目类别:
Novel virulence and exoenzyme regulators
新型毒力和外酶调节剂
  • 批准号:
    8070413
  • 财政年份:
    2010
  • 资助金额:
    $ 38.62万
  • 项目类别:
Novel virulence and exoenzyme regulators
新型毒力和外酶调节剂
  • 批准号:
    8648986
  • 财政年份:
    2010
  • 资助金额:
    $ 38.62万
  • 项目类别:
Novel virulence and exoenzyme regulators
新型毒力和外酶调节剂
  • 批准号:
    8460550
  • 财政年份:
    2010
  • 资助金额:
    $ 38.62万
  • 项目类别:
Novel virulence and exoenzyme regulators
新型毒力和外酶调节剂
  • 批准号:
    7980364
  • 财政年份:
    2010
  • 资助金额:
    $ 38.62万
  • 项目类别:
Role of the SasAB locus in S. aureus Biofilms
SasAB 基因座在金黄色葡萄球菌生物膜中的作用
  • 批准号:
    6834009
  • 财政年份:
    2004
  • 资助金额:
    $ 38.62万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 38.62万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 38.62万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 38.62万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 38.62万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 38.62万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 38.62万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 38.62万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 38.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 38.62万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 38.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了